Differential toxicity of antracyclines on cultured endothelial cells

Endothelium: Journal of Endothelial Cell Research

Volumn 11, Issue 5-6, 2004, Pages 253-258

  Kaushal, Varsha ^a,b   Kaushal, G P ^a,b   Mehta, Paulette ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Doxil; Doxorubicin; Endothelial cells; Mcl 1; p53

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CASPASE 3; DAUNORUBICIN; DNA FRAGMENT; DOXORUBICIN; IDARUBICIN; LIPOSOME; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MCL 1; ANTHRACYCLINE; CASP3 PROTEIN, HUMAN; CASPASE; PROTEIN P53;

APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL DAMAGE; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CORONARY ARTERY; DRUG CYTOTOXICITY; DRUG FORMULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NICK END LABELING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; WESTERN BLOTTING; DRUG EFFECT; METABOLISM; TIME; VASCULAR ENDOTHELIUM;

ANTHRACYCLINES; CASPASE 3; CASPASES; CELL SURVIVAL; DNA FRAGMENTATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 12344272684     PISSN: 10623329     EISSN: None     Source Type: Journal    
DOI: 10.1080/10623320490904124     Document Type: Article

References (25)

1. Adams J.M., and Cory S. (1998) The Bcl-2 protein family: Arbiters of cell survival. Science, 281, 1322-1326.
2. Datta S.R., Brunet A., and Greenberg M.E. (1999) Cellular survival: A play in three Akts. Genes and Development, 13, 2905-2927.
3. Hortobagyi G.N. (1997) Anthracyclines in the treatment of cancer. An overview. Drugs, 54(Suppl 4), 1-7.
4. Iarussi D., Indolfi P., Casale F., Coppolino R., Tedesco M.A., and Di Tullio, M.T. (2001) Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Current Medical Chemistry 8, 1649-1660.
5. Johnson S.A., and Richardson D.S. (1998) Anthracyclines in haematology: Pharmacokinetics and clinical studies. Blood Reviews, 12, 52-71.
6. Kaushal G.P., Kaushal V., Hong X., and Shah SN. (2001) Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney International, 60, 1726-1736.
7. Kaushal V., Kaushal G.P., Melkaveri S.N., and Mehta P. (2004) Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. Joural of Thrombosis and Haemostay, 2, 327-334.
8. Kotamraju S., Konorev E.A., Joseph J., and Kalyanaraman B. (2000) Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. Journal of Biological Chemistry 275, 33585-33592.
9. Kremer L.C., and Caron H.N. (2004) Anthracycline cardiotoxicity in children. New England Journal of Medicine, 351, 120-121.
10. Kwok J.C., and Richardson D.R. (2000) The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity. Redox Report, 5, 317-324.
11. Lorenzo E., Ruiz-Ruiz C., Quesada A.J., Hernandez G., Rodriguez A., Lopez-Rivas A., and Redondo J.M. (2002) Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. Journal of Biological Chemistry, 277, 10883-10892.
12. Olson R.D., and Mushlin P.S. (1990) Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB Journal, 4, 3076-3086.
13. Safra T. (2003) Cardiac safety of liposomal anthracyclines. Oncologist, 8 (Suppl 2), 17-24.
14. Seymour L., Bramwell V., and Moran L.A. (1999) Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prevention and Control 3, 145-159.
15. Speyer J., and Wasserheit C. (1998) Strategies for reduction of anthracycline cardiac toxicity. Seminars in Oncology, 25, 525-537.
16. Swain S.M., Whaley F.S., Gerber M.C., Weisberg S., York M., Spicer D., Jones S.E., Wadler S., Desai A., Vogel C., Speyer J., Mittelman A., Reddy S., Pendergrass K., Velez-Garcia E., Ewer M.S., Bianchine J.R., and Gams R.A. (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. Journal of Clinical Oncology, 15, 1318-1332.
17. Swift L., McHowat J., and Sarvazyan N. (2003) Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity. Cancer Research, 63, 5992-5998.
18. Theodoulou M., and Hudis C. (2004) Cardiac profiles of liposomal anthracyclines. Cancer, 100, 2052-2063.
19. Wakabayashi I., and Groschner K. (2003) Vascular actions of anthracycline antibiotics. Current Medical Chemistry, 10, 427-436.
20. Wang S., Konorev E.A., Kotamraju S., Joseph J., Kalivendi S., and Kalyanaraman, B. (2004) Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. Intermediacy of H(2)O(2)- and p53-dependent pathways. Journal of Biological Chemistry 279, 25535-25543.
21. Weiss R.B. (1992) The anthracyclines: Will we ever find a better doxorubicin? Seminars in Oncology, 19, 670-686.
22. Wojtacki J., Lewicka-Nowak E., and Lesniewski-Kmak K. (2000) Anthracycline-induced cardiotoxicity: Clinical course, risk factors, pathogenesis, detection and prevention - review of the literature. Medical Science Monitor 6, 411-420.
23. Wolf B.B., Schuler M., Echeverri F., and Green D.R. (1999) Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. Journal of Biological Chemistry, 274, 30651-30656.
24. Wu S., Ko Y.S., Teng M.S., Ko Y.L., Hsu L.A., Hsueh C., Chou Y.Y., Liew C.C., and Lee Y.S. (2002) Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and In vivo studies. Journal Molecualr and Cellular Cardiology, 34, 1595-1607.
25. Zucchi R., and Danesi R. (2003) Cardiac toxicity of antineoplastic anthracyclines. Current Medical Chemistry and Anti-Cancer Agents, 3, 151-171.